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ABSTRACT 
Purpose - To synthesize potent bentothiazole derivatives screened to possess anti-convulsant activity as a way 
forward for treatment of epilepsy.  
Method: The present work emphasizes on synthesis of 
Results: The MES activity indicated significant anticonvulsant activity for all of the test compounds. However, 
they were found to be less potent when compared with the reference standard Phenytoin. Within the series A, B, 
C and D compounds of series B with substitution of -F at 6
new series of 2-amino-6-substituted benzothiazole  (A-D) 
by using 4-substituted aniline and potassium thiocyanate in presence of bromine in glacial acetic acid which 
further treated with various substituted aromatic aldehydes in presence of glacial acetic acid to get the 2-imino-
benzothiazole derivatives (2A to 2I).  (6-Substituted-benzothiazol-2-yl)-(4-substituted-benzylidene)-amine 
derivatives obtained from the reactional sequence were injected intraperitoneally into mice and evaluated by the 
maximal electroshock (MES), neurotoxicity screen using rotarod at the dose of 30 mg/kg. Phenytoin was used 
as the standard for the comparison at the dose level of 25 mg/kg. 
th
Conclusion: All the compounds showed protections against seizures in the range 50-75% indicative of the 
promising nature of the compounds against seizure spread. Thus it can be concluded that substitution of 6
 position of benzothiazole showed maximum 
potency. 
th
KEYWORDS 
-
position with fluoro, chloro, bromo and nitro groups (A-D) at the terminal benzothiazole ring is beneficial for 
anticonvulsant activity. 
Benzothiazole, Schiff base, anticonvulsant, neurotoxicity, max. electroshock seizure (MES). 
INTRODUCTION 
Epilepsy has been recognized as a neurological disorder, affecting a large section of people both males and 
females across the world. Every year approximately 2,50,000 new cases are added to this figure. Many patients 
have seizures that are resistant to the available medical therapies. Newer drugs such as Topiramate, Zonisamide 
and Vigabatrin have emerged as promising anticonvulsants. Despite introduction of these new drugs women of 
child bearing age and chronic patients face specific problems of neurotoxicity, symptoms of depression and 
CNS related ailments. Therefore, it is essential to search for newer chemical entities for the treatment of 
epilepsy
1. Benzothiazole nucleus has resulted in a large number of compounds having diverse pharmacological 
activities viz. antibacterial
2, antifungal
3, anthelmintic
4, antitumour
5, anti-inflammatory
6, antitubercular
7
Many anticonvulsants may be placed in the category of the Schiff bases. A common structural feature is the 
presence of conjugation, usually aromatic ring associated with the imine double bond, which increases the 
reduction potential of the iminium form. Iminium form is active against partial seizures
 etc.  
8.  In the 2-imino 
benzothiazole derivatives, the pharmacophoric element is thought to be a lipophilic aryl ring. The attachment of 
a second aryl ring, designated as the distal ring to the proximal aryl ring, increases the van der waal’s bonding at 
the binding site and may also increase potency
9
The chemistry and biological potencies of 2-amino benzothiazole as important class of compounds have been 
studied.  This article is focused on exploring as there is very less understanding known about 2-amino 
benzothiazole having  an  imine group at the 2 position.  So in the present study, 2-imino benzothiazole 
derivatives will be evaluated for their anticonvulsant properties. 
.  
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The chemicals required were obtained from Hi-media Chem. Ltd, SD-Fine Ltd. and Sigma Aldrich Pvt. Ltd. and 
were used as such. Melting points were determined using open capillary melting point apparatus and are 
uncorrected. Reactions were monitored by thin layer chromatography (TLC) on silica gel G plates using 
methanol : chloroform (0.3 : 9.7), methanol : chloroform (1:9) with iodine vapors in UV chamber for visualizing 
spots. After physical characterization, the compounds were subjected to spectral analysis. Proton Nuclear 
Magnetic resonance spectra were recorded on Bruker WM-300 (at 300 MHz) spectrometer and chemical shifts 
were reported in parts per million (δ value) from TMS (δ 0ppm for 
1H NMR) as an internal standard. Coupling 
constant were given in Hertz. Mass spectra were recorded on a JEOL-SX-102 instrument using ESI. Infrared 
spectra were taken on Perkin-Elmer AX-1 spectrometer and values are expressed in cm
-1
Syntheses of 6-substituted-1,3-benzothiazole-2-amines (A-D) 
.  
Substituted anilines (0.01 mol) and potassium thiocyanate (0.01 mol) were dissolved in glacial acetic acid, 
cooled and stirred for 15 min. Cold bromine solution (0.01 mol, 3 mL in 10 mL acetic acid) was added 
dropwise. The mixture was continuously stirred for additional 3 h. Separated hydrochloride salt was filtered off, 
washed with acetic acid, dissolved in hot water and neutralized with aqueous ammonium solution (25%). The 
resulting precipitate was filtered off, washed with water and recrystallized from ethanol to get the desired 
compounds (A-D). The progress of reaction was monitored by TLC using methanol : chloroform (1:9). 
10, 11 
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Scheme 1
(A-D)
 
6-chloro-benzothiazol-2-ylamine (A) 
Yield: 52%, melting range 184-186°C. IR (KBr pellet) (Ar) C=C str, 1458.0 cm-1; C=N str, 
1650.7 cm-1; (Aromatic) N-H str, 3412.5 cm-1. ESI m/z: 185.30 (M+ peak). 
6-Fluoro-benzothiazol-2-ylamine (B) 
Yield: 45%, melting range 178-180°C. IR (KBr pellet) (Ar) C=C str, 1449.9 cm-1; C=N str, 
1603.8 cm-1; (Aromatic) N-H str, 3439.8 cm-1. 
6-Bromo-benzothiazol-2-ylamine (C) 
Yield: 84%, melting range 164-166°C. IR (KBr pellet) (Ar) C=C str, 1444.58 cm-1; C=N str, 
1633.59 cm-1; (Aromatic) N-H str, 3452.34 cm-1. 
6-Nitro-benzothiazol-2-ylamine (D) 
Yield: 60%, melting range 198-200°C. IR (KBr pellet) (Ar) C=C str, 1572.8 cm-1; C=N str, 
1650.0 cm-1; (Aromatic) N-H str, 3436.6 cm-1. ESI m/z: 196.2 (M+ peak). 
Syntheses of 2-imino-benzothiazole derivatives (2A-I) 
The compound (0.01  mol) 6-substituted-benzothiazol-2-ylamine  (A-D)  and (0.01mol) substituted  aromatic 
aldehydes were refluxed in ethanol (20 ml) for 9-10 hrs. The resultant solution was cooled and solid was 
precipitated out. The solid substance was filtered and recrystallised by ethanol. The progress of reaction was 
monitored by TLC using methanol : chloroform (0.3:9.7). 
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(6-Chloro-benzothiazol-2-yl)-(4-Chloro-benzylidene)-amine (2A) 
Yield: 78%, melting range 200-202°C. IR (KBr pellet) (Aliphatic) C-H str, 2854.45 cm-1; C=N str, 1616.24 cm-
1; (Aromatic) C=C str, 1558.38 cm-1. ESI m/z: 309.0025 (M+ peak). 
1H NMR (CDCl3
(6-Chloro-benzothiazol-2-yl)-(4-dimethylamino-benzylidene)-amine (2B) 
): δ 7.425-7.88 (m, 3H), 
δ 7.816-7.978 (m, 4H), δ 9.035 (s, H) . 
Yield: 60%, melting range 206-208°C. IR (KBr pellet) (Aliphatic) C-H str, 2854.45 cm-1; C=N str, 1659.23 cm-
1; (Aromatic) C=C str, 1529.45 cm-1. ESI m/z: 316.0870 (M+ peak). 
1H NMR (CDCl3
(6-Chloro-benzothiazol-2-yl)-(4-methoxy-benzylidene)-amine (2C) 
): δ 3.1083 (s, 6H), δ 
6.7145-7.3948 (m, 3H), δ 7.7489-7.8996 (m, 4H), δ 8.8248 (s, H).  
Yield:40%, melting range 130-132°C. IR (KBr pellet) (Aliphatic) C-H str, 2923.88 cm-1; C=N str,1593.09 cm-
1; (Aromatic) C=C str, 1515.94 cm-1. ESI m/z: 303.2934 (M+ peak). 
1H NMR (CDCl3
(6-Chloro-benzothiazol-2-yl)-(2-methyl-benzylidene)-amine (2D) 
): δ 3.115 (s, 3H), δ 
7.298-7.484 (m, 4H), δ 7.812-8.205 (m, 3H), δ 9.365 (s, H)  
Yield: 34%, melting range 168-170°C. IR (KBr pellet) (Aliphatic) C-H str, 3060.82 cm-1; C=N str,1589.23 cm-
1; (Aromatic) C=C str, 1529.45 cm-1. ESI m/z: 287.0598 (M+ peak). 
1H NMR (CDCl3
(6-Fluoro-benzothiazol-2-yl)-(4-chloro-benzylidene)-amine (2E) 
): δ 2.698 -2.898 (s, 3H), 
δ 7.298 (d, 1H), δ 7.340-7.365 (d, 1H),  δ 7.419-7.484 (m, 2H), δ 7.812-7.818 (d, 1H), δ 7.868-7.897 (d, 1H), 
8.180-8.205 (d, 1H),  δ 9.364 (s, H).  
Yield: 40%, melting range 192-194°C. IR (KBr pellet) (Aliphatic) C-H str, 2923.88 cm-1; C=N str, 1616.24 cm-
1; (Aromatic) C=C str, 1591.16 cm-1. ESI m/z: 303.2934 (M+ peak). 
1H NMR (CDCl3
(6-Fluoro-benzothiazol-2-yl)-(4-dimethylamino-benzylidene)-amine (2F) 
): δ 3.115 (s, 3H), δ 
7.298-7.484 (m, 4H), δ 7.812-8.205 (m, 3H), δ 9.365 (s, H). 
Yield: 66%, melting range 188-190°C. IR (KBr pellet) (Aliphatic) C-H str, 2912.31 cm-1; C=N str, 1616.24 cm-
1; (Aromatic) C=C str, 1569.95 cm-1. ESI m/z: 291.332 (M+ peak). 
1H NMR (CDCl3
(6-Fluoro-benzothiazol-2-yl)-(4-methoxy-benzylidene)-amine (2G) 
): δ 3.114 (s, 6H), δ 6.725-
6.753 (d, 2H), δ 7.128-7.186 (t, 1H), δ 7.466-7.493 (d, 1H), δ 7.747-7.907 (m, 3H), δ 8.823 (s, H). 
Yield: 54%, melting range 134-136°C. IR (KBr pellet) (Aliphatic) C-H str, 2837.09 cm-1; C=N str, 1595.02 cm-
1; (Aromatic) C=C str, 1560.30 cm-1. ESI m/z: 287.0598 (M+ peak). 
1H NMR (CDCl3
(6-Bromo-benzothiazol-2-yl)-(4-dimethylamino-benzylidene)-amine (2H) 
): δ 3.128 (s, 3H), δ 
6.725-6.753 (d, 1H), δ 7.128-7.186 (t, 3H), δ 7.466-7.493 (d, 1H), δ 7.757- 7.907 (t, 2H), δ 8.827 (s, H).  
Yield: 78%, melting range 180-182°C. IR (KBr pellet) (Aliphatic) C-H str, 2921.96 cm-1; C=N str, 1612.38 cm-
1; (Aromatic) C=C str, 1569.95 cm-1. ESI m/z: 362.0418 (M+ peak). 
1H NMR (CDCl3
(6-Nitro-benzothiazol-2-yl)-(4-dimethylamino-benzylidene)-amine (2I) 
): δ 3.117 (s, 6H), δ 
6.723-6.751 (d, 2H), δ 7.505-7.534 (d, 1H),  δ 7.739-7.768 (d, 1H) 7.879-7.909 (d, 3H), δ 8.839 (s, 1H). 
Yield: 70%, melting range 144-146°C. IR (KBr pellet) (Aliphatic) C-H str, 2921.96 cm-1; C=N str, 1664.45 cm-
1; (Aromatic) C=C str, 1602.74 cm-1. ESI m/z: 327.1151 (M+ peak). 
1H NMR (CDCl3
 
): δ 3.093-3.145 (s, 6H), 
δ 6.739-7.590(m, 4H), δ 8.212-8.718 (m, 3H), δ 8.899 (s, H).  
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Anticonvulsant activity- Anticonvulsant evaluation was undertaken using a reported procedure
12-14.  Albino 
mice (swiss, 25-30) were used in groups of five each as experimental animals. The test compounds and standard 
drug were suspended in 0.5% methyl cellulose-water mixture and administered intraperitoneally. The animals 
were maintained on an adequate diet and allowed free access to food and water except during the short time they 
were removed from cages for testing. The animals were maintained at room temperature (25+2 
0
Maximum electroshock seizure test (MES)- Maximum electroshock seizure was elicited with a 60 cycle 
alternating current of 50 mA intensity delivered for 0.25 sec. via ear clip electrodes. Maximal seizure typically 
consists of a short period of tonic extension of the hind limbs and final clonic episodes. Abolition of the hind 
limb tonic extensor component of the seizure is defined as protection and the results are expressed as % 
protection. 
c).  
Neurotoxicity (NT)- The rotarod test was used to evaluate neurotoxicity. The animal was placed on a 3.2 cm 
diameter knurled rod rotating at 6 rpm. Normal mice can remain indefinitely on a rod rotating at this speed. 
Neurological toxicity is defined as the failure of the animals to remain on the rod for 1 min. Results are 
expressed as the number of animals exhibiting toxicity/ number of animals tested.  
Table 1:  Anticonvulsant and neurotoxicity screening of 2-imino-benzothiazole derivatives 
 
 
  
 
   
 
 
 
 
Please note: 
Values are expressed as Mean ± SEM (N=5) (compared to Control group) by using One way Analysis of 
Variance (ANOVA) followed by Dunnett's Multiple Comparison Test P< 0.01*. 
(-) absence of activity; × not tested 
Fig 1: Graphical representation of anticonvulsant activity by Maximum electroshock seizure 
 
 
Compound No.  MES screen protection 
(%) 
Neurotoxicity screen 
2A  56.27%  (-) 
2B  70.32%  (-) 
2C  67.87%  (-) 
2D  64.36%  (-) 
2E  58.03%  (-) 
2F  75.45%  (-) 
2G  72.09%  (-) 
2H  56.05%  (-) 
2I  51.20%  (x) 
Ranjana Singh et al. / International Journal of Pharma Sciences and Research (IJPSR)
ISSN : 0975-9492 Vol 5 No 05 May 2014  216RESULTS AND DISCUSSION 
 (6-Substituted-benzothiazol-2-yl)-(4-substituted -benzylidene)-amine derivatives obtained from the reactional 
sequence were injected intraperitoneally into mice and evaluated by the maximal electroshock (MES), 
neurotoxicity screen using rotarod at the dose of 30 mg/kg body mass and observations were carried out at 45 
min after the compound administration. The result of anticonvulsant activity and neurotoxicity was presented in 
table 1. Phenytoin was used as the standard for the comparison at the dose level of 25 mg/kg. The MES activity 
indicated significant anticonvulsant activity for all of the test compounds. However, they were found to be less 
potent when compared with the reference standard Phenytoin. Within the series A, B, C and D compounds of 
series B with substitution of -F at 6
th position of benzothiazole showed maximum potency. the 2F with -F at 6
th 
position of benzothiazole moiety and -N(CH3)2 at the 4
th position of the phenyl ring was the most active due to 
increase in lipophilicity, which could further increase penetration through the blood brain barrier. Among the 
derivatives of A series, 2B was found to be most active, which has similar substitution at 4
th
CONCLUSION 
 position of phenyl 
ring as was in 2F. However the compounds 2H and 2I were less active than derivatives of B and A series. The 
highest activity of derivatives of series B may be attributed due to the presence of the fluoro group. In the 
neurotoxicity studies, none of the compounds displayed neurotoxicity since they successfully passed the rotarod 
test without any sign of motor impairment.  
Various  (6-Substituted-benzothiazol-2-yl)-(4-substituted  -benzylidene)-amine derivatives were designed and 
synthesized starting from various  substituted  aromatic aldehydes. Structures of all the compounds were 
confirmed on the basis of spectral and elemental analyses. All the newly synthesized compounds were screened 
for their anticonvulsant activity and were compared with the standard drug Phenytoin. Interestingly, all the 
compounds showed protections against seizures in the range 50-75% indicative of the promising nature of the 
compounds against seizure spread. Compound 2F showed highest protection against MES induced seizures. The 
synthesis of number of 2-amino-6-substituted benzothiazole (A-D) derivatives as candidate anticonvulsant has 
been reported in this study. The results suggest that minor changes to structure can increase or decrease the 
activity. Thus it can be concluded that substitution of 6
th
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